Palatin Technologies to Present at 10th Annual BIO Investor Forum

CRANBURY, N.J., Oct. 21, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 10th Annual BIO Investor Forum on Wednesday, October 26, 2011 at 2:00 p.m. Pacific Time.  Hosted by the Biotechnology Industry Organization (BIO), the 10th Annual BIO Investor Forum will take place October 25-26 at the Palace Hotel in San Francisco, CA. 

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs.  Palatin Technologies has an ongoing Phase 2B clinical trial with bremelanotide, a peptide melanocortin receptor agonist, for treatment of female sexual dysfunction in premenopausal women.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

 

SOURCE Palatin Technologies, Inc.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.